Biogen Inc.

BIIB

Held by 6 specialist biotech funds

High Convergence

6 funds opened new positions. Next phase3 readout (natalizumab): Mar 2004. Short interest: 4.5% of float.

Drug Manufacturers - GeneralCEO: Christopher A. ViehbacherIPO: 1991Website ↗

Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides SPINRAZA, while FUMADERM is available for the treatment of plaque psoriasis. Among its other key offerings is ADUHELM, specifically developed for Alzheimer's disease. The company also markets a selection of biosimilar drugs, including BENEPALI (an etanercept biosimilar akin to ENBREL), IMRALDI (an adalimumab biosimilar comparable to HUMIRA), and FLIXABI (an infliximab biosimilar referencing REMICADE). Further extending its therapeutic reach, Biogen supplies RITUXAN, prescribed for conditions like non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, certain types of ANCA-associated vasculitis, and pemphigus vulgaris. RITUXAN HYCELA targets non-Hodgkin's lymphoma and CLL, and GAZYVA is utilized for CLL and follicular lymphoma. OCREVUS addresses both relapsing and primary progressive forms of MS, complementing the company's broader efforts in anti-CD20 therapies. The company maintains a robust research and development pipeline, featuring numerous investigational therapies. These candidates are designed to tackle a wide spectrum of conditions, including multiple sclerosis and neuroimmunological disorders (e.g., BIIB135, BIIB061, BIIB091, BIIB107), Alzheimer's disease and other forms of dementia (e.g., Aducanumab, Lecanemab, BIIB076, BIIB080), neuromuscular disorders (e.g., BIIB067, BIIB078, BIIB105, BIIB100, BIIB110), Parkinson's disease and related movement disorders (e.g., BIIB124, BIIB094, BIIB118, BIIB101, BIIB122), neuropsychiatric conditions (e.g., BIIB125, BIIB104), immunology-related illnesses (e.g., Dapirolizumab pegol, BIIB059), acute neurological events (e.g., BIIB093, BIIB131), and neuropathic pain (e.g., BIIB074). Additionally, several biosimilar candidates, such as BYOOVIZ, BIIB800, and SB15, are progressing through various developmental stages. Biogen actively engages in strategic collaborations and licensing arrangements with various partners, including Acorda Therapeutics, Inc., Alkermes Pharma Ireland Limited, Denali Therapeutics Inc., Eisai Co., Ltd., Genentech, Inc., Neurimmune SubOne AG, Ionis Pharmaceuticals, Inc., Samsung Bioepis Co., Ltd., Sangamo Therapeutics, Inc., and Sage Therapeutics, Inc. Established in 1978, Biogen Inc. maintains its corporate headquarters in Cambridge, Massachusetts.

Catalysts

Phase 3PositiveQ3 2003natalizumabCrohn's DiseaseNCT00032799

Enrollment:905/905Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 3PositiveQ1 2004natalizumabCrohn's DiseaseNCT00032786

RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q2 2004natalizumabCrohn's DiseaseNCT00055367

Enrollment:Target 30Sites: 13NON_RANDOMIZED, TREATMENT

Phase 3PositiveQ4 2004NatalizumabMultiple Sclerosis, Relapsing-RemittingNCT00027300

Primary: The primary objectives of this study are to determine whether natalizumab, when compared with placebo, is effective in reducing the rate of clinical relapses at 1 year and, in slowing the progression of disability at 2 years. (1 year and 2 years)Enrollment:900/900Sites: 53RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q1 2006Interferon Beta-1aChronic Inflammatory Demyelinating PolyradiculoneuropathyNCT00099489

Primary: The primary endpoint for the efficacy analyses is the total IVIg dose (g/Kg) administered after Visit 5 and through Visit 9 (Week 32, End of Study).Enrollment:Target 67Sites: 20RANDOMIZED, DOUBLE, TREATMENT

Phase 2PositiveQ1 2006BG00012Multiple SclerosisNCT00168701

Primary: The primary endpoint for the primary objective is the total number of MRI lesions at Weeks 12, 16, 20, and 24. (Weeks 12, 16, 20, and 24)Enrollment:260/260Sites: 42RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q2 2007BG9924Rheumatoid ArthritisNCT00292422

Primary: To evaluate the safety and tolerability of BG9924 when administered in combination with MTX to subjects with active RA who have had an inadequate response to DMARD therapyEnrollment:50/50Sites: 10RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q4 2007BG00002-E (natalizumab high titer)Multiple SclerosisNCT00516893

Primary: Number of Participants With Anti-Natalizumab Antibody Negative, Transient Positive, and Persistent Positive Status (Assessed every 12 weeks from Week 0 (Baseline) to Week 36)Enrollment:113/113Sites: 13NA

Phase 3PositiveQ4 2007BG00002 (natalizumab)Multiple Sclerosis, Relapsing-RemittingNCT00306592

Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious AEs (SAEs) (Baseline through Week 48)Enrollment:404/404Sites: 63NA, TREATMENT

Phase 2Q4 2008Baminercept alfa 1Rheumatoid ArthritisNCT00664716

Primary: Evaluate efficacy of BG9924 in combination with methotrexate (MTX) in RA participants who have had an inadequate response to DMARD therapy (3 months)Enrollment:391/391Sites: 8RANDOMIZED, DOUBLE, TREATMENT

Phase 2NegativeQ4 2008BG9924Rheumatoid ArthritisNCT00458861

Primary: Evaluate efficacy of BG9924 in combination with methotrexate in RA participants who have had an inadequate response to anti-TNF therapy (26 weeks)Enrollment:115/115Sites: 1RANDOMIZED, TRIPLE, TREATMENT

Phase 3NegativeQ1 2010Galiximab in combination with rituximabLymphoma, Non-Hodgkin'sNCT00363636

Primary: To assess efficacy as measured by progression free survival (PFS), and determine whether rituximab plus galiximab compared to rituximab plus placebo may extend PFS. (The duration of this study is approx 4 years)Enrollment:340/340RANDOMIZED, TRIPLE, TREATMENT

Phase 2NegativeQ2 2010Lumiliximab + FCRChronic Lymphocytic LeukemiaNCT00801060

Primary: To evaluate the safety and tolerability of FCR+L compared with FCR alone in subjects with previously untreated CLL. (June 2010)Enrollment:40/40Sites: 36RANDOMIZED, TREATMENT

Phase 3PositiveQ1 2011BG00012Relapsing-Remitting Multiple SclerosisNCT00420212

Primary: Proportion of Subjects Relapsed (2 years)Enrollment:1,234/1,234Sites: 159RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q4 2011natalizumabRelapsing Remitting Multiple SclerosisNCT01071083

Primary: Time Course to Return of Radiological and/or Clinical Evidence of Multiple Sclerosis Activity, as Measured by the Percentage of Subjects Who Met Magnetic Resonance Imaging (MRI) and/or Clinical Relapse Rescue Criteria. (28 Weeks)Enrollment:175/175Sites: 33RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2PositiveQ1 2012dimethyl fumarateRelapsing-Remitting Multiple Sclerosis, Multiple SclerosisNCT01156311

Primary: Summary of Treatment-emergent Adverse Events (TEAEs) Occurring Post-BG00012 Dosing (Add-on Therapy Period) (AEs were collected from enrollment until the final study visit (Week 26 +/-5 days).)Enrollment:108/108Sites: 16NON_RANDOMIZED, TREATMENT

Phase 3NegativeQ2 2012BG00002 (natalizumab)Relapsing Remitting Multiple SclerosisNCT01058005

Primary: Incidence of Treatment-emergent Serious Adverse Events (SAEs) (up to 108 Weeks)Enrollment:84/84Sites: 42RANDOMIZED

Phase 3ApprovedQ2 2012BIIB041 (Fampridine-SR)Multiple SclerosisNCT01235221

Primary: Adverse events (AEs) and serious adverse events (SAEs) as well as Changes in vital signs and clinical laboratory assessments (From Screening (Day 0) to Termination (Month 27))Enrollment:38/38Sites: 5NA, TREATMENT

Phase 3PositiveQ4 2012BIIB017 (peginterferon beta-1a)Relapsing Multiple SclerosisNCT00906399

Primary: Annualized Relapse Rate (ARR) at 1 Year (1 Year)Enrollment:1,516/1,516Sites: 178RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q2 2014natalizumab IVRelapsing-Remitting Multiple SclerosisNCT01405820

Primary: Cumulative Number of Combined Unique Active Lesions (Up to Week 60)Enrollment:290/290Sites: 64RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q3 2014Omaveloxolone Ophthalmic Suspension 1.0%Inflammation and Pain Following Ocular SurgeryNCT02065375

Primary: Absence of Anterior Chamber Cells at Day 15 (Visit 5) (15 days after the participant receives the first dose)Enrollment:109/109Sites: 6RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q1 2015Corneal Endothelial Cell Loss, Ocular Pain, Ocular InflammationNCT02128113

Primary: Change From Baseline in Central Corneal Endothelial Cell Counts (12 weeks)Enrollment:307/307Sites: 15RANDOMIZED, DOUBLE, PREVENTION

Phase 2NegativeQ1 2015natalizumabAcute Ischemic StrokeNCT01955707

Primary: Change in Infarct Volume From Baseline (Diffusion-Weighted Imaging [DWI]) to Day 5 (Fluid-Attenuated Inversion Recovery [FLAIR]) (Baseline, Day 5)Enrollment:161/161Sites: 50RANDOMIZED, DOUBLE, TREATMENT

Phase 3PositiveQ4 2015peginterferon beta-1aRelapsing Multiple SclerosisNCT01332019

Primary: Number of Participants Experiencing Adverse Events (AEs) Serious AEs, and Discontinuations Due to AEs (up to 4 years)Enrollment:1,077/1,077Sites: 151NON_RANDOMIZED, TREATMENT

Phase 2NegativeQ1 2016BIIB023Lupus NephritisNCT01930890

Primary: Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs) (Up to Week 108)Enrollment:87/87Sites: 33RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q1 2016fampridineMultiple SclerosisNCT02219932

Primary: Proportion of Participants Achieving a Mean Improvement of ≥ 8 Points From Baseline on the Multiple Sclerosis Walking Scale (MSWS-12) Over 24 Weeks (Baseline to 24 weeks)Enrollment:646/646Sites: 87RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q3 2016BIIB019 (Daclizumab)Relapsing-Remitting Multiple SclerosisNCT01051349

Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuation Due to AEs, Withdrawals Due to AEs (Baseline up to 24 weeks after last dose of treatment (Up to 300 weeks))Enrollment:410/410Sites: 65NA, TREATMENT

Phase 2PositiveQ4 2016BIIB074Primary Inherited ErythromelalgiaNCT02917187

Primary: Weekly average severity of paroxysms (Day 1 to Week 12)Enrollment:8/8Sites: 5RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q2 2017dimethyl fumarateMultiple Sclerosis, Relapsing-Remitting, Multiple SclerosisNCT02525874

Primary: Change From Baseline in Lymphocyte Subsets Counts up to 48 Weeks: T Cell, B Cell, Natural Killer Cell (TBNK) (Baseline, Week 4, Week 8, Week 12, Week 24, Week 36 and Week 48)Enrollment:218/218Sites: 34NA, TREATMENT

Phase 2PositiveQ3 2017nusinersenSpinal Muscular AtrophyNCT01839656

Primary: Percent of Participants Who Achieved Improvement in Motor Milestones as Assessed by Section 2 of the HINE at the Last Visit (Day 1352 or Early Termination)Enrollment:21/21Sites: 4NON_RANDOMIZED, TREATMENT

Phase 2PositiveQ4 2017SAGE-217Major DepressionNCT03000530

Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) - Part A (Day 1 up to Day 21)Enrollment:102/102Sites: 8RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q4 2017Omaveloxolone capsules, 2.5 mgMItochondrial MyopathiesNCT02255422

Primary: Change of Peak Workload (in Watts/kg) During Exercise Testing (12 weeks)Enrollment:53/53Sites: 9RANDOMIZED, DOUBLE, TREATMENT

Phase 3NegativeQ3 2018BIIB019 (Daclizumab)Relapsing-Remitting Multiple Sclerosis, Multiple SclerosisNCT01797965

Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) (First dose of study drug in Study 303 to within 180 days of last dose (up to approximately 5.5 years))Enrollment:1,501/1,501Sites: 222NA, TREATMENT

Phase 2ApprovedQ3 2018NusinersenSpinal Muscular AtrophyNCT02462759

Phase 3NegativeQ3 2019Aducanumab (BIIB037)Alzheimer's DiseaseNCT02484547

Primary: Change From Baseline in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) Score at Week 78 (Baseline, Week 78)Enrollment:1,643/1,643Sites: 180RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2NegativeQ3 2019BIIB092Supranuclear Palsy, ProgressiveNCT03068468

Primary: Change From Baseline in Progressive Supranuclear Palsy Rating Scale (PSPRS) at Week 52 (Baseline, Week 52)Enrollment:490/490Sites: 86RANDOMIZED, DOUBLE, TREATMENT

Phase 3NegativeQ3 2020Bardoxolone methylPulmonary HypertensionNCT03068130

Primary: Long Term Safety as Measured by Incidence and Severity of Adverse Events During the Duration of the Study (From time of first dose until the final visit, up to 172 weeks)Enrollment:261/261Sites: 96NA, TREATMENT

Phase 3Q4 2020Alport SyndromeNCT03019185

Primary: Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) After 12 Weeks of Treatment (Phase 2) (Baseline through 12 weeks after participant receives the first dose in the Phase 2 study)Enrollment:187/187Sites: 63RANDOMIZED, TRIPLE, TREATMENT

Phase 2NegativeQ4 2020Parkinson's DiseaseNCT03318523

Phase 3Q4 2020ChoroideremiaNCT03496012

Phase 3Q2 2021ALKS 8700Multiple SclerosisNCT02634307

Primary: Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) (From first dose to two weeks after last dose of study drug (Up to 98 weeks))Enrollment:1,057/1,057Sites: 115NA, TREATMENT

Phase 2Q4 2021Bardoxolone methyl oral capsuleChronic Kidney DiseasesNCT04702997

Primary: Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 12 (Baseline through 12 weeks after participant receives the first dose)Enrollment:81/81Sites: 12RANDOMIZED, TRIPLE, TREATMENT

Phase 3PositiveQ4 2021SAGE-217Depressive Disorder, MajorNCT04476030

Primary: Change From Baseline in the HAMD-17 Total Score at Day 3 (Baseline, Day 3)Enrollment:440/440Sites: 51RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ1 2022SAGE-217Depression, PostpartumNCT04442503

Phase 2Q1 2022BIIB104Cognitive Impairment Associated With SchizophreniaNCT03745820

Phase 3PositiveQ2 2023SAGE-217Major Depressive DisorderNCT03864614

Phase 3NegativeQ3 2023Bardoxolone methylChronic Kidney Diseases, Alport Syndrome, Autosomal Dominant Polycystic KidneyNCT03749447

Phase 2Q4 2023MOR202Glomerulonephritis, Membranous Nephropathy, anti PLA2R PositiveNCT04733040

Phase 3Q1 2024NusinersenMuscular Atrophy, SpinalNCT04089566

Primary: Part B Infantile-onset SMA: Change From Baseline in CHOP-INTEND Total Score for 50/28mg Nusinersen Versus CS3B Matched Sham Control Group (Baseline, Day 183)Enrollment:145/145Sites: 45RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q3 2024TofersenALS Caused by Superoxide Dismutase 1 (SOD1) MutationNCT03070119

Phase 2NegativeQ3 2024BIIB105Amyotrophic Lateral SclerosisNCT04494256

Phase 3Q3 2024Diroximel fumarateRelapsing Forms of Multiple SclerosisNCT05083923

Primary: Part 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) (Baseline (Day 1) up to Week 24 (for prematurely discontinued participants, AEs were reported up to 2 weeks post discontinuation))Enrollment:136/136Sites: 52NA, TREATMENT

Phase 2Q3 2024Relapsing Multiple SclerosisNCT04079088

Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) (First dose of study drug to end of the study (Up to Week 84))0RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q4 2024NusinersenSpinal Muscular AtrophyNCT02386553

Primary: Time to Death or Respiratory Intervention (Screening up to Day 2891)Enrollment:25/25Sites: 21NA, PREVENTION

Phase 3Q3 2025BIIB074Trigeminal NeuralgiaNCT03637387

Phase 2Q1 2026BIIB091Relapsing Forms of Multiple SclerosisNCT05798520

Phase 2Q1 2026BIIB122Parkinson DiseaseNCT05348785

Primary: Time to Confirmed Worsening in Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts II and III Combined Score Over the Treatment Period (Up to Week 144)Enrollment:650/650Sites: 113RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Apr 30, 2026BIIB122 225 mgParkinson DiseaseNCT06602193

Primary: Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) with BIIB122 compared with placebo over the 12-week double-blind period (12 weeks)Enrollment:Target 50Sites: 20RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q2 2026BIIB080Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease DementiaNCT05399888

Primary: Dose response in Change From Baseline to Week 76 on the CDR-SB (Baseline to Week 76)Enrollment:416/416Sites: 138RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q2 2026Choroideremia, X-Linked Retinitis PigmentosaNCT03584165

Phase 3Q3 2026NusinersenMuscular Atrophy, SpinalNCT04729907

Phase 3Q3 2026LitifilimabLupus Erythematosus, SystemicNCT04961567

Primary: Percentage of Participants Who Achieved a Systemic Lupus Erythematosus Responder Index of 4 (SRI-4) Response at Week 52 (Week 52)Enrollment:562/562Sites: 177RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q3 2026LitifilimabLupus Erythematosus, SystemicNCT04895241

Primary: Percentage of Participants Who Achieved a Systemic Lupus Erythematosus Responder Index of 4 (SRI-4) Response at Week 52 (Week 52)Enrollment:548/548Sites: 164RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q4 2026LitifilimabSubacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus ErythematosusNCT05531565

Primary: Parts A: Percentage of Participants who Achieve a Cutaneous Lupus Activity of Physician's Global Assessment-Revised (CLA-IGA-R) Erythema Score of 0 or 1 (Week 16)Enrollment:Target 450Sites: 315RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q4 2026FelzartamabAntibody-mediated RejectionNCT06685757

Primary: Part A: Percentage of Participants Who Achieve Biopsy-proven Histologic Resolution (BPHR) (Week 24)Enrollment:132/132Sites: 56RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q1 2027TofersenALS (Amyotrophic Lateral Sclerosis)NCT07294144

Primary: Proportion of participants with ≥30% reduction in plasma NfL (From Baseline to Week 28)Enrollment:Target 30Sites: 3NA, TREATMENT

Phase 3Q1 2027baricitinib treatmentRheumatoid ArthritisNCT04870203

Primary: Proportion of patients who achieve an ACR 50 response (At weeks 24 after baseline)Enrollment:160/160Sites: 36RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q2 2027BIIB017 (peginterferon beta-1a)Multiple Sclerosis, Relapsing-RemittingNCT03958877

Primary: Part 1: Annualized Relapse Rate (ARR) at Week 48 (Week 48)Enrollment:152/152Sites: 65RANDOMIZED, TREATMENT

Phase 3Q2 2027FelzartamabImmunoglobulin A Nephropathy (Ig AN)NCT06935357

Phase 3Q3 2027TofersenAmyotrophic Lateral Sclerosis Associated With a SOD1 Gene MutationNCT04856982

Phase 3Q3 2027NusinersenSpinal Muscular AtrophyNCT05067790

Phase 2Oct 31, 2027Tyruko Injectable ProductMultiple Sclerosis, Clinically Isolated Syndrome of DemyelinationNCT05418010

Phase 3Q4 2027OmaveloxoloneFriedreich AtaxiaNCT06953583

Phase 2Q1 2028FelzartamabGraves' DiseaseNCT07722546

Phase 2Q1 2028FelzartamabMicrovascular InflammationNCT07219043

Phase 3Q2 2028SalanersenSpinal Muscular AtrophyNCT07444476

Phase 3Q4 2028SalanersenMuscular Atrophy, SpinalNCT07221669

Phase 3Dec 21, 2028LecanemabPreclinical Alzheimer's Disease, Early Preclinical Alzheimer's DiseaseNCT04468659

Phase 3Q2 2029BIIB059 (litifilimab)Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus ErythematosusNCT06044337

Phase 3Jun 30, 2029Lecanemab IVEarly Alzheimer's DiseaseNCT03887455

Phase 3Q3 2029SalanersenMuscular Atrophy, SpinalNCT07444450

Phase 3Q1 2030FelzartamabPrimary Membranous NephropathyNCT06962800

Primary: Percentage of Participants who Achieve Complete Remission (CR) at Week 104 (Week 104)Enrollment:Target 180Sites: 112RANDOMIZED, TREATMENT

Phase 3Q1 2030LitifilimabSystemic Lupus Erythematosus (SLE)NCT05352919

Primary: Number of Participants with Treatment Emergent Adverse Events (TEAEs) (Up to Week 284)Enrollment:Target 864Sites: 213RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q2 2031FelzartamabAntibody-mediated Rejection, Microvascular InflammationNCT07444489

Phase 3Q3 2034Diroximel FumarateRelapsing Forms of Multiple SclerosisNCT07483632

Primary: TP Cohort A and OLE Period: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and AEs Leading to Treatment Discontinuation (Cohort A: From first dose of study drug up to end of follow-up (up to Week 104), OLE: Baseline (Week 96) up to the end of OLE period (up to Week 196))Enrollment:Target 185RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2TBDRTA 402 Dose1Malignant MelanomaNCT00535314

Primary: To determine the proportion of patients without progression at 6 months in patients with unresectable Stage III or Stage IV melanoma treated with RTA 402.0RANDOMIZED, TREATMENT

Phase 2TBDSecondary Progressive Multiple SclerosisNCT01181089

Primary: Measure: Change in cerebrospinal fluid levels of secondary lymphoid organs chemokines from baseline with baminercept relative to placebo (after 4 months of treatment)0RANDOMIZED, TRIPLE, TREATMENT

Phase 3TBDrituximabLow-Grade or Follicular B-Cell Non-Hodgkin's LymphomaNCT00168740

Primary: overall response rateEnrollment:Target 150Sites: 31NON_RANDOMIZED, TREATMENT

Phase 3NegativeTBDZevalin (ibritumomab tiuxetan)Non-Hodgkin's LymphomaNCT00057343

Primary: Event-free survivalEnrollment:Target 400Sites: 67RANDOMIZED, TREATMENT

Biogen Inc.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Conferences

Recent News & Research

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research